Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | The evolving CLL treatment paradigm

Carsten Niemann • 9 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Venetoclax

Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, highlights novel targeted therapies in development for chronic lymphocytic leukemia (CLL), the movement of the field over the past decade and the application of combining targeted therapies to improve patient outcomes. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Carsten Niemann

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
3:20
Explainable machine learning to identify CLL-driven changes on the gut microbiome
Carsten Niemann • 6 Oct 2023
3:27
The implementation of a data-driven CLL-TIM algorithm into an EPIC-based electronic health record
Carsten Niemann • 6 Oct 2023
2:25
Monitoring infection risk in patients with CLL & insights into the PreVent-ACaLL trial
Carsten Niemann • 6 Oct 2023

Related Videos

1:17
The curative potential of alloSCT in the treatment of HR-MDS
Jurjen Versluis • 22 Apr 2024
10:34
Remission induction therapy prior to alloSCT in AML: insights from the ASAP trial
Johannes Schetelig • 19 Apr 2024
1:57
The FORUM trials: results of F1 and plans for F2
Christina Peters • 15 Apr 2024
5:28
Young matched unrelated donors versus older-aged matched sibling donors in alloSCT with PTCy
Karthik Nath • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals